A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

NCT00631462 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: TG101348

Sponsor

TargeGen